Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: a retrospective cohort study.
Fusco JP, Castañón E, Carranza OE, Zubiri L, Martín P, Espinós J, Rodríguez J, Santisteban M, Aramendía JM, Gil-Bazo I. Fusco JP, et al. Among authors: zubiri l. J Neurooncol. 2013 Dec;115(3):429-35. doi: 10.1007/s11060-013-1241-0. Epub 2013 Sep 15. J Neurooncol. 2013. PMID: 24037499
Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed.
Arévalo E, Castañón E, López I, Salgado J, Collado V, Santisteban M, Rodríguez-Ruiz M, Martín P, Zubiri L, Patiño-García A, Rolfo C, Gil-Bazo I. Arévalo E, et al. Among authors: zubiri l. J Transl Med. 2014 Apr 14;12:98. doi: 10.1186/1479-5876-12-98. J Transl Med. 2014. PMID: 24726028 Free PMC article.
Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.
Castañón E, Rolfo C, Viñal D, López I, Fusco JP, Santisteban M, Martin P, Zubiri L, Echeveste JI, Gil-Bazo I. Castañón E, et al. Among authors: zubiri l. J Transl Med. 2015 Aug 7;13:257. doi: 10.1186/s12967-015-0622-x. J Transl Med. 2015. PMID: 26248464 Free PMC article.
Immune responses in checkpoint myocarditis across heart, blood and tumour.
Blum SM, Zlotoff DA, Smith NP, Kernin IJ, Ramesh S, Zubiri L, Caplin J, Samanta N, Martin S, Wang M, Tirard A, Song Y, Xu KH, Barth J, Sen P, Slowikowski K, Tantivit J, Manakongtreecheep K, Arnold BY, Nasrallah M, Pinto CJ, McLoughlin D, Jackson M, Chan P, Lawless A, Michaud WA, Sharova T, Nieman LT, Gainor JF, Wu CJ, Juric D, Mino-Kenudson M, Oliveira G, Sullivan RJ, Boland GM, Stone JR, Thomas MF, Neilan TG, Reynolds KL, Villani AC. Blum SM, et al. Among authors: zubiri l. Nature. 2024 Dec;636(8041):215-223. doi: 10.1038/s41586-024-08105-5. Epub 2024 Nov 6. Nature. 2024. PMID: 39506125
Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records.
Sun VH, Heemelaar JC, Hadzic I, Raghu VK, Wu CY, Zubiri L, Ghamari A, LeBoeuf NR, Abu-Shawer O, Kehl KL, Grover S, Singh P, Suero-Abreu GA, Wu J, Falade AS, Grealish K, Thomas MF, Hathaway N, Medoff BD, Gilman HK, Villani AC, Ho JS, Mooradian MJ, Sise ME, Zlotoff DA, Blum SM, Dougan M, Sullivan RJ, Neilan TG, Reynolds KL. Sun VH, et al. Among authors: zubiri l. J Clin Oncol. 2024 Dec 10;42(35):4134-4144. doi: 10.1200/JCO.24.00326. Epub 2024 Sep 3. J Clin Oncol. 2024. PMID: 39226489
Identification of Immune Checkpoint Inhibitor-Induced Diabetes.
Ruiz-Esteves KN, Shank KR, Deutsch AJ, Gunturi A, Chamorro-Pareja N, Colling CA, Zubiri L, Perlman K, Ouyang T, Villani AC, Florez JC, Gusev A, Reynolds KL, Miller KK, Udler MS, Sise ME, Rengarajan M. Ruiz-Esteves KN, et al. Among authors: zubiri l. JAMA Oncol. 2024 Oct 1;10(10):1409-1416. doi: 10.1001/jamaoncol.2024.3104. JAMA Oncol. 2024. PMID: 39207773
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study.
Wan G, Chen W, Khattab S, Roster K, Nguyen N, Yan B, Rajeh A, Seo J, Rashdan H, Zubiri L, Hadfield MJ, Demehri S, Yu KH, Lotter W, Gusev A, LeBoeuf NR, Reynolds KL, Kwatra SG, Semenov YR. Wan G, et al. Among authors: zubiri l. Lancet Oncol. 2024 Aug;25(8):1053-1069. doi: 10.1016/S1470-2045(24)00278-X. Epub 2024 Jul 15. Lancet Oncol. 2024. PMID: 39025103
Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis.
Thomas MF, Slowikowski K, Manakongtreecheep K, Sen P, Samanta N, Tantivit J, Nasrallah M, Zubiri L, Smith NP, Tirard A, Ramesh S, Arnold BY, Nieman LT, Chen JH, Eisenhaure T, Pelka K, Song Y, Xu KH, Jorgji V, Pinto CJ, Sharova T, Glasser R, Chan P, Sullivan RJ, Khalili H, Juric D, Boland GM, Dougan M, Hacohen N, Li B, Reynolds KL, Villani AC. Thomas MF, et al. Among authors: zubiri l. Nat Med. 2024 May;30(5):1349-1362. doi: 10.1038/s41591-024-02895-x. Epub 2024 May 9. Nat Med. 2024. PMID: 38724705 Free PMC article.
86 results